| Accession |
PRJCA015654 |
| Title |
A Phase III, multi-center, randomized, double-blind, 48 week study to evaluate the safety and efficacy of osilodrostat in patients with Cushing's disease |
| Relevance |
Medical |
| Data types |
PK analysis
|
| Organisms |
Homo sapiens
|
| Description |
A Phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushing's disease. The study aimed to demonstrate the superiority of osilodrostat compared to placebo in achieving a complete response at Week 12, to evaluate the safety of osilodrostat compared to placebo, and to evaluate the long-term safety and efficacy of osilodrostat. |
| Sample scope |
PK analysis sample |
| Release date |
2023-04-16 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| No funding support
|
|
|
|
|
|
| Submitter |
Xiao Hui
Guo (bdyyguoxiaohui@sina.com)
|
| Organization |
Peking University First Hospital |
| Submission date |
2023-03-17 |
